The Development of a Novel Diagnostic Assay That Utilizes a Pseudotyped Vesicular Stomatitis Virus for the Detection of Neutralizing Activity against Crimean-Congo Hemorrhagic Fever Virus

Suda, Yuto; Chamberlain, John; Dowall, Stuart; Saijo, Masayuki; Horimoto, Taisuke; Hewson, Roger; Shimojima, Masayuki

doi:10.7883/yoken.jjid.2017.354

Cited by 6 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As real CCHFV-neutralization assays involve the manipulation of live CCHFV and require professional operators under BSL-4 containment, which are not currently available in our laboratory, CCHFVpv (a pseudotyped VSV bearing the CCHFV envelope GP) showed similar neutralizing activities with the real CCHFV in the detection of six serum samples obtained from patients in Tajikistan with confirmed CCHF, and Chamberlain et al. thought that neutralization assays using CCHFVpv in BSL-2 laboratories can be used as a convenient alternative to assays using infectious CCHFV in BSL-4 facilities ( Suda et al., 2018 ). In addition, the reliability of using recombinant VSV instead of the authentic virus to detect SARS-CoV-2 specific neutralizing antibodies has been shown in other studies ( Case et al., 2020 ; Dieterle et al., 2020 ; Li et al., 2020 ; He et al., 2023 ).…”

Section: Discussionmentioning

confidence: 94%

Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein

Wang,

Shi

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

IntroductionThe Crimean-Congo hemorrhagic fever virus (CCHFV), the most geographically widespread tick-borne virus, is endemic in Africa, Eastern Europe and Asia, with infection resulting in mortality in up to 30% of cases. Currently, there are no approved vaccines or effective therapies available for CCHF. The CCHFV should only be manipulated in the BSL-4 laboratory, which has severely hampered basic seroprevalence studies. MethodsIn the present study, two antibody detection methods in the forms of an enzyme-linked immunosorbent assay (ELISA) and a surrogate virus neutralization test (sPVNT) were developed using a recombinant glycoprotein (rGP) and a vesicular stomatitis virus (VSV)-based virus bearing the CCHFV recombinant glycoprotein (rVSV/CCHFV) in a biosafety level 2 (BSL-2) laboratory, respectively. ResultsThe rGP-based ELISA and rVSV/CCHFV-based sVNT were established by using the anti-CCHFV pre-GC mAb 11E7, known as a broadly cross-reactive, potently neutralizing antibody, and their applications as diagnostic antigens were validated for the specific detection of CCHFV IgG and neutralizing antibodies in experimental animals. In two tests, mAb clone 11E7 (diluted at 1:163840 or 512) still displayed positive binding and neutralization, and the presence of antibodies (IgG and neutralizing) against the rGP and rVSV/CCHFV was also determined in the sera from the experimental animals. Both mAb 11E7 and animal sera showed a high reactivity to both antigens, indicating that bacterially expressed rGP and rVSV/CCHFV have good immunoreactivity. Apart from establishing two serological testing methods, their results also demonstrated an imperfect correlation between IgG and neutralizing antibodies. DiscussionWithin this limited number of samples, the rGP and rVSV/CCHFV could be safe and convenient tools with significant potential for research on specific antibodies and serological samples.

show abstract

Section: Discussionmentioning

confidence: 94%

Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein

Wang,

Shi

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…ELISA results are considered consistent with acute infection if either CCHFV IgM is detected or a 4-fold increase in CCHFV IgG titers occurs between serial blood samples. Some CCHFV antibody assays are known to cross-react with Nairobi sheep disease serogroup, which also causes human disease in some CCHF endemic areas, and with Hazara virus, a member of the CCHFV group with no documented human disease ( 18 ). Several ELISA kits are commercially available for research but not for clinical diagnostic testing, and their sensitivity and specificity are also susceptible to CCHFV genetic variability ( 16 ).…”

Section: Methodsmentioning

confidence: 99%

Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Diagnosis, Clinical Management, and Therapeutics

Frank,

Weaver,

Raabe

2024

Emerg. Infect. Dis.

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever virus (CCHFV) is the most geographically widespread tickborne viral infection worldwide and has a fatality rate of up to 62%. Despite its widespread range and high fatality rate, no vaccines or treatments are currently approved by regulatory agencies in the United States or Europe. Supportive treatment remains the standard of care, but the use of antiviral medications developed for other viral infections have been considered. We reviewed published literature to summarize the main aspects of CCHFV infection in humans. We provide an overview of diagnostic testing and management and medical countermeasures, including investigational vaccines and limited therapeutics. CCHFV continues to pose a public health threat because of its wide geographic distribution, potential to spread to new regions, propensity for genetic variability, potential for severe and fatal illness, and limited medical countermeasures for prophylaxis and treatment. Clinicians should become familiar with available diagnostic and management tools for CCHFV infections in humans.

show abstract

“…Neutralizing antibodies to CCHF may be measured using pseudoplaque or plaque reduction neutralization tests or CCHF viral-like particles (81)(82)(83). Neutralization assays using viral-like particles may be performed using BSL2 precautions (82).…”

Section: Cchf Serological Testingmentioning

confidence: 99%

Diagnostic Testing for Crimean-Congo Hemorrhagic Fever

Raabe

2020

J Clin Microbiol

View full text Add to dashboard Cite

Crimean-Congo hemorrhagic fever is the most geographically widespread tick-borne virus, with infection resulting in mortality in up to 30% of cases. Clinical diagnosis alone is difficult due to the nonspecific nature of symptoms; therefore, laboratory diagnostics should be utilized for patients with residence in or travel to regions of endemicity in whom the disease is suspected. This minireview provides an overview of laboratory tests available for Crimean-Congo hemorrhagic fever (CCHF) and their utility in diagnosis with a focus on diagnosing CCHF in humans.

show abstract

The Development of a Novel Diagnostic Assay That Utilizes a Pseudotyped Vesicular Stomatitis Virus for the Detection of Neutralizing Activity against Crimean-Congo Hemorrhagic Fever Virus

Cited by 6 publications

References 27 publications

Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein

Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein

Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Diagnosis, Clinical Management, and Therapeutics

Diagnostic Testing for Crimean-Congo Hemorrhagic Fever

Contact Info

Product

Resources

About